Aleix Prat: Excited to share the results of the SOLTI-ELIPSE trial
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a post on LinkedIn:
“Excited to share the results of the SOLTI-ELIPSE trial, just published in AACR Journals Clinical Cancer Research!
Our study evaluated elacestrant, a selective estrogen receptor degrader (SERD), in the preoperative setting for estrogen receptor-positive (ER-positive), HER2-negative early breast cancer.
Key Findings:
- Elacestrant achieved a Complete Cell Cycle Arrest (CCCA) rate of 27.3%, with a significant reduction in Ki67 (-52.9%).
- The treatment induced a shift toward a more endocrine-sensitive and less proliferative tumor phenotype, as shown by PAM50-based gene signatures.
- Elacestrant enhanced the expression of immune-response genes while suppressing proliferation and estrogen-signaling pathways.
- Safety profile: Most adverse events were mild (grade 1), with only one grade 3 rash leading to treatment discontinuation.
Why this matters:
These results demonstrate the potential of elacestrant in early-stage breast cancer, showing both biological and molecular responses, and highlight its manageable safety profile. This paves the way for further investigation of elacestrant in the early setting.
A huge thank you to the 2 PIs (Maria Vidal and Meritxell Bellet), all collaborators and patients who made this study possible, especially the team at SOLTI and my lab Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).
Together, we are advancing the future of breast cancer care.”
Authors: Maria Vidal, Claudette Falato, Tomás Pascual, Rodrigo Sanchez-Bayona, Montserrat Muñoz-Mateu, Isaac Cebrecos, Xavier Gonzalez-Farré, Tomás Cortadellas, Mireia Margelí Vila, Miguel A. Luna, Christian Siso, Kepa Amillano, Patricia Galván, Milana A. Bergamino, Juan M. Ferrero-Cafiero, Fernando Salvador, Alejandra Espinosa Guerrero, Laia Pare, Esther Sanfeliu, Aleix Prat, Meritxell Bellet.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023